234 related articles for article (PubMed ID: 27697464)
21. Targeting the kallikrein-related peptidases for drug development.
Sotiropoulou G; Pampalakis G
Trends Pharmacol Sci; 2012 Dec; 33(12):623-34. PubMed ID: 23089221
[TBL] [Abstract][Full Text] [Related]
22. Expression and localization of tissue kallikrein mRNAs in human epidermis and appendages.
Komatsu N; Takata M; Otsuki N; Toyama T; Ohka R; Takehara K; Saijoh K
J Invest Dermatol; 2003 Sep; 121(3):542-9. PubMed ID: 12925213
[TBL] [Abstract][Full Text] [Related]
23. Keratinocyte-specific mesotrypsin contributes to the desquamation process via kallikrein activation and LEKTI degradation.
Miyai M; Matsumoto Y; Yamanishi H; Yamamoto-Tanaka M; Tsuboi R; Hibino T
J Invest Dermatol; 2014 Jun; 134(6):1665-1674. PubMed ID: 24390132
[TBL] [Abstract][Full Text] [Related]
24. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade.
Eissa A; Amodeo V; Smith CR; Diamandis EP
J Biol Chem; 2011 Jan; 286(1):687-706. PubMed ID: 20940292
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of kallikrein-related peptidase 7 (KLK7) mRNA expression in advanced high-grade serous ovarian cancer.
Gong W; Liu Y; Diamandis EP; Kiechle M; Bronger H; Dorn J; Dreyer T; Magdolen V
J Ovarian Res; 2020 Oct; 13(1):125. PubMed ID: 33087135
[TBL] [Abstract][Full Text] [Related]
26. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.
Deraison C; Bonnart C; Lopez F; Besson C; Robinson R; Jayakumar A; Wagberg F; Brattsand M; Hachem JP; Leonardsson G; Hovnanian A
Mol Biol Cell; 2007 Sep; 18(9):3607-19. PubMed ID: 17596512
[TBL] [Abstract][Full Text] [Related]
27. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
[TBL] [Abstract][Full Text] [Related]
28. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy.
Komatsu N; Saijoh K; Kuk C; Shirasaki F; Takehara K; Diamandis EP
Br J Dermatol; 2007 May; 156(5):875-83. PubMed ID: 17459012
[TBL] [Abstract][Full Text] [Related]
29. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
Gouin O; Barbieux C; Leturcq F; Bonnet des Claustres M; Petrova E; Hovnanian A
J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475
[TBL] [Abstract][Full Text] [Related]
30. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes.
Nin M; Katoh N; Kokura S; Handa O; Yoshikawa T; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):17-24. PubMed ID: 19118981
[TBL] [Abstract][Full Text] [Related]
31. Novel inhibitory activity for serine protease inhibitor Kazal type-3 (Spink3) on human recombinant kallikreins.
Assis DM; Zalazar L; Juliano MA; De Castro R; Cesari A
Protein Pept Lett; 2013 Oct; 20(10):1098-107. PubMed ID: 23590280
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of kallikrein-related peptidases by the serine protease inhibitor of Kazal-type 6.
Kantyka T; Fischer J; Wu Z; Declercq W; Reiss K; Schröder JM; Meyer-Hoffert U
Peptides; 2011 Jun; 32(6):1187-92. PubMed ID: 21439340
[TBL] [Abstract][Full Text] [Related]
33. SPINK9: a selective, skin-specific Kazal-type serine protease inhibitor.
Brattsand M; Stefansson K; Hubiche T; Nilsson SK; Egelrud T
J Invest Dermatol; 2009 Jul; 129(7):1656-65. PubMed ID: 19194479
[TBL] [Abstract][Full Text] [Related]
34. Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, KLK5 and KLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function.
Dong Y; Matigian N; Harvey TJ; Samaratunga H; Hooper JD; Clements JA
Biol Chem; 2008 Feb; 389(2):99-109. PubMed ID: 18163887
[TBL] [Abstract][Full Text] [Related]
35. Expression of serine protease inhibitors in epidermal keratinocytes is increased by calcium but not 1,25-dihydroxyvitamin D
Kobashi M; Morizane S; Sugimoto S; Sugihara S; Iwatsuki K
Br J Dermatol; 2017 Jun; 176(6):1525-1532. PubMed ID: 27797397
[TBL] [Abstract][Full Text] [Related]
36. Profiling system for skin kallikrein proteolysis applied in gene-deficient mouse models.
Horn M; Zbodakova O; Kasparek P; Srp J; Haneckova R; Hradilek M; Mares M; Sedlacek R
Biol Chem; 2018 Sep; 399(9):1085-1089. PubMed ID: 29885275
[TBL] [Abstract][Full Text] [Related]
37. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
[TBL] [Abstract][Full Text] [Related]
38. Increased mass levels of certain serine proteases in the stratum corneum in acute eczematous atopic skin.
Voegeli R; Doppler S; Joller P; Breternitz M; Fluhr JW; Rawlings AV
Int J Cosmet Sci; 2011 Dec; 33(6):560-5. PubMed ID: 21699549
[TBL] [Abstract][Full Text] [Related]
39. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.
Avgeris M; Scorilas A
Expert Opin Ther Targets; 2016 Jul; 20(7):801-18. PubMed ID: 26941073
[TBL] [Abstract][Full Text] [Related]
40. Novel Biological Substrates of Human Kallikrein 7 Identified through Degradomics.
Yu Y; Prassas I; Dimitromanolakis A; Diamandis EP
J Biol Chem; 2015 Jul; 290(29):17762-17775. PubMed ID: 26032414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
